Document Detail


Pediatric cardiovascular safety: Challenges in drug and device development and clinical application.
MedLine Citation:
PMID:  23067905     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Development of pediatric medications and devices is complicated by differences in pediatric physiology and pathophysiology (both compared with adults and within the pediatric age range), small patient populations, and practical and ethical challenges to designing clinical trials. This article summarizes the discussions that occurred at a Cardiac Safety Research Consortium-sponsored Think Tank convened on December 10, 2010, where members from academia, industry, and regulatory agencies discussed important issues regarding pediatric cardiovascular safety of medications and cardiovascular devices. Pediatric drug and device development may use adult data but often requires additional preclinical and clinical testing to characterize effects on cardiac function and development. Challenges in preclinical trials include identifying appropriate animal models, clinically relevant efficacy end points, and methods to monitor cardiovascular safety. Pediatric clinical trials have different ethical concerns from adult trials, including consideration of the subjects' families. Clinical trial design in pediatrics should assess risks and benefits as well as incorporate input from families. Postmarketing surveillance, mandated by federal law, plays an important role in both drug and device safety assessment and becomes crucial in the pediatric population because of the limitations of premarketing pediatric studies. Solutions for this wide array of issues will require collaboration between academia, industry, and government as well as creativity in pediatric study design. Formation of various epidemiologic tools including registries to describe outcomes of pediatric cardiac disease and its treatment as well as cardiac effects of noncardiovascular medications, should inform preclinical and clinical development and improve benefit-risk assessments for the patients. The discussions in this article summarize areas of emerging consensus and other areas in which consensus remains elusive and provide suggestions for additional research to further our knowledge and understanding of this topic.
Authors:
Katherine E Bates; Victoria L Vetter; Jennifer S Li; Susan Cummins; Fernando Aguel; Christopher Almond; Anne M Dubin; Josephine Elia; John Finkle; Elizabeth A Hausner; Francesca Joseph; Abraham M Karkowsky; Matthew Killeen; Jodi Lemacks; Lisa Mathis; Ann W McMahon; Ellen Pinnow; Ignacio Rodriguez; Norman L Stockbridge; Margaret Stockwell; Melissa Tassinari; Mitchell W Krucoff
Related Documents :
10643135 - Catch a falling apple: isaac newton and myths of genius.
15748405 - Botulinum toxin treatment of urethral and bladder dysfunction.
11777115 - Deny nothing, doubt everything: a comment on westen and morrison (2001).
17066755 - The many secure knowledge bases of psychotherapy.
17766625 - Acog committee opinion no. 377: research involving women.
16688175 - Future fitness and helping in social queues.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American heart journal     Volume:  164     ISSN:  1097-6744     ISO Abbreviation:  Am. Heart J.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  481-92     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2012 Mosby, Inc. All rights reserved.
Affiliation:
Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA. Electronic address: bateske1@email.chop.edu.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Study design for the "effect of METOprolol in CARDioproteCtioN during an acute myocardial InfarCtion...
Next Document:  Regionalization of post-cardiac arrest care: Implementation of a cardiac resuscitation center.